ArticleFEBS open bio2026
IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor 2 (IGF2) is implicated in osteosarcoma, but direct functional evidence of its role is lacking. Here, we used CRISPR-Cas9 to knock out IGF2 in Saos2 osteosarcoma cells. Knockout cells showed reduced proliferation in vitro which was fully restored by exogenous IGF2. In vivo, knockout xenografts reached only ~25% of wild-type tumor volume. Furthermore, transcriptomic analysis revealed depletion of angiogenesis-related genes but no major changes in IGF2 pathway components. Finally, while integration with receptor dependency data suggested alternative signaling pathways, IGF2 loss remained functionally limiting. These findings demonstrate that IGF2 promotes osteosarcoma proliferation and tumor growth but is not strictly essential for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.